The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States.
BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros.
In the dynamic realm where technology meets humanity, we are seeing a new frontier called digital twins. These AI-driven entities, also known as digital humans or synthetic clones, are reshaping the future of education, research, and training across nearly every sector, including the pharmaceutical and life sciences industries.
The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it.
AstraZeneca’s blockbuster BTK inhibitor Calquence significantly improved progression-free survival when used as a frontline treatment in patients with mantle cell lymphoma, according to Thursday’s late-stage results.
Following strong Phase II data, Amgen is going all in on its next-generation obesity treatment MariTide, with plans to run a Phase III trial and a separate mid-stage study for diabetes.